A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
Latest Information Update: 13 Aug 2024
Price :
$35 *
At a glance
- Drugs Bepirovirsen (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms B-Together
- Sponsors GlaxoSmithKline; GSK
- 14 Nov 2023 Results presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Nov 2023 Results of the HBsAg response for patients by viral genotype, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Nov 2023 End of study results presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.